Ferox 20 ml IV Injection/Infus Injection

About Ferox 20 ml IV Injection/Infus 1000 mg/20 ml

Ferox 20 ml IV Injection/Infus contains ferric carboxymaltose, an iron replacement medicine given into a vein. It belongs to the parenteral iron preparations and is used in adults with certain types of iron deficiency anaemia.

There are 15 brands of Ferric Carboxymaltose listed in Bangladesh. The lowest listed price is Ferium Injection 500 mg/10 ml at ৳ 700 per unit.

What is Ferox 20 ml IV Injection/Infus 1000 mg/20 ml?

Ferox 20 ml IV Injection/Infus is a parenteral iron preparation. Its active ingredient is ferric carboxymaltose, a form of iron that is given into a vein rather than by mouth. It is available as an injection/infusion with a strength of 1000 mg/20 ml and is made by Advanced Chemical Industries PLC. Iron is needed to make haemoglobin, which carries oxygen in the blood. When body iron stores fall, anaemia can develop. This medicine is given by healthcare professionals in a clinical setting, where the patient can be monitored during and after administration.

Uses of Ferox 20 ml IV Injection/Infus

Ferox is indicated for treating iron deficiency anaemia in adults who cannot tolerate iron taken by mouth or who have not responded well to it. It is also indicated for adults with iron deficiency anaemia and non-dialysis dependent chronic kidney disease. Whether it is suitable for a particular person is decided by the doctor after assessment. It is not a general tonic and should not be used without a confirmed need for iron replacement.

How to use Ferox 20 ml IV Injection/Infus

Ferox is given by a healthcare professional into a vein as an injection or infusion, not at home. The doctor decides the dose and course, including how the doses are spaced and whether treatment is repeated. Because serious reactions can occur, patients are monitored during and after administration. Do not attempt to use or adjust this medicine yourself. Ask the doctor or pharmacist if you have questions about how it will be given and what to expect afterwards.

Side effects of Ferox 20 ml IV Injection/Infus

Some people may have nausea, vomiting, headache, dizziness, flushing, itching, rash, hives, wheezing, constipation, low blood pressure, a bitter taste, injection site discolouration, or changes in blood phosphorus and liver enzyme tests. Serious allergic-type reactions, including anaphylactic-type reactions, have been reported and can be life-threatening. Tell the healthcare team straight away if you feel unwell during or after the infusion. The doctor or pharmacist can explain more about these effects.

Safety and precautions

Ferox must not be used by anyone with a hypersensitivity to any of its ingredients. Serious hypersensitivity reactions can occur, so monitoring during and after administration is needed, and it should only be given where staff and treatments for such reactions are immediately available. It is pregnancy category C; animal studies showed adverse effects on the fetus, human data are limited, and use in pregnancy depends on the doctor's judgement of benefits and risks. Tell the doctor about allergies, pregnancy, breastfeeding and other medicines before treatment.

Frequently asked questions

What is Ferox 20 ml IV Injection/Infus used for, and what kind of medicine is it?

It is a parenteral iron preparation containing ferric carboxymaltose. It is indicated for iron deficiency anaemia in adults who cannot tolerate or do not respond well to oral iron, and in adults with non-dialysis dependent chronic kidney disease. The doctor decides whether it is suitable.

Who should avoid it or ask the doctor first?

Anyone with a hypersensitivity to any of its ingredients should not receive it. Because serious hypersensitivity reactions can occur, tell the doctor about allergies and any other medical conditions. Pregnant or breastfeeding women, and anyone taking other medicines, should speak to the doctor before treatment.

What do the dosage form and strength mean?

Ferox is supplied as an injection/infusion, so it is given into a vein by a healthcare professional. The strength is 1000 mg/20 ml, which describes the amount of medicine in each vial as labelled. The doctor decides the dose and course; do not use it yourself.

How is Ferox given, and what monitoring is needed?

It is given into a vein as an injection or infusion by a healthcare professional, not at home. Patients are monitored for signs of hypersensitivity during and after administration. The doctor decides the dose, the spacing of doses and whether treatment should be repeated.

Indications

Ferric Carboxymaltose is indicated for the treatment of iron deficiency anemia in adult patients-
  • Who have intolerance to oral iron or have had unsatisfactory response to oral iron
  • Who have non-dialysis dependent chronic kidney disease.

Pharmacology

Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.

Dosage & Administration

For patients weighing 50 kg or more: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.

For patients weighing less than 50 kg: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.

The dosage of Ferric Carboxymaltose is expressed in mg of elemental iron. Each mL of Ferric Carboxymaltose contains 50 mg of elemental iron. Ferric Carboxymaltose treatment may be repeated if iron deficiency anemia reoccurs.

Administer Ferric Carboxymaltose intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.

When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferric Carboxymaltose solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.

Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferric Carboxymaltose is intended for single use only. Any unused drug remaining after injection must be discarded.

Avoid extravasation of Ferric Carboxymaltose since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferric Carboxymaltose administration at that site.

Interaction

There are no known drug interactions and none well documented.

Contraindications

Hypersensitivity to any of its components.

Side Effects

Nausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactions

Pregnancy & Lactation

Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Precautions & Warnings

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.

Hypertension: 
Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.

Storage Conditions

Do not store above 30°C. Do not freeze.

Alternative brands of Ferric Carboxymaltose

Other brands with the same generic name, cheapest first.

See all 15 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.